A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults with Atopic Dermatitis
Latest Information Update: 21 Mar 2025
At a glance
- Drugs APB-R3 (Primary)
- Indications Atopic dermatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Evommune
Most Recent Events
- 17 Mar 2025 According to an Evommune media release, company announced enrollment of the first patient.
- 26 Feb 2025 Status changed from not yet recruiting to recruiting.
- 25 Jun 2024 New trial record